PDCD1 and leukemia: In an immunocompetent murine leukemia model, guadecitabine (a second-generation HMA) negatively regulates inhibitory accessory cells in TME by reducing PD-1+ T cells and the AML-mediated expansion of myeloid-derived suppressor cells.